MYCOLab Ai Logo - gold and army green

In vitro activity of SF001: a next-generation polyene versus amphotericin B

Summary

This study tested a new antifungal drug called SF001 against a well-established antifungal called amphotericin B. Researchers tested both drugs against common fungal infections affecting vulnerable patients. SF001 was found to work as well as or better than amphotericin B, particularly against harder-to-treat Aspergillus fungi, while potentially causing fewer side effects.

Background

Invasive fungal infections (IFIs) represent a significant clinical challenge with increasing incidence in immunosuppressed populations. Amphotericin B (AmB) remains the gold standard for treating severe IFIs despite its high toxicity. SF001 is a next-generation polyene designed to maintain broad-spectrum fungicidal activity while reducing toxicity through selective ergosterol extraction.

Objective

This study compared the in vitro activity of SF001 and amphotericin B against clinical isolates of Candida and Aspergillus species, including AmB-resistant strains, to evaluate SF001’s potential as a safer alternative antifungal agent.

Results

SF001 demonstrated activity comparable to AmB against Candida species (MIC50/90 of 0.25/1 mg/L versus 0.5/0.5 mg/L for AmB). However, Aspergillus isolates showed higher susceptibility to SF001 than AmB (MIC50/90 of 0.5/1 mg/L versus 1/4 mg/L for AmB), notably including AmB-resistant species such as A. terreus and A. flavus.

Conclusion

SF001 demonstrates potent in vitro fungicidal activity against both Candida and Aspergillus species, with particular efficacy against AmB-resistant Aspergillus strains. Combined with its improved safety profile, SF001 represents a promising candidate for further development as a next-generation antifungal therapy for invasive fungal infections.
  • Published in:Antimicrobial Agents and Chemotherapy,
  • Study Type:In vitro comparative study,
  • Source: 40261080
Scroll to Top